Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada

CompletedOBSERVATIONAL
Enrollment

305

Participants

Timeline

Start Date

April 25, 2013

Primary Completion Date

August 15, 2017

Study Completion Date

August 15, 2017

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
OTHER

No intervention

Trial Locations (26)

T3M 1M4

South Health Campus/Alberta Health Services/ University of Calgary, Calgary

T5J 3S9

Edmonton Respiratory Consultants & Edmonton Sleep Lab, Edmonton

T6L 5X8

Grey Nuns Community Hospital, Edmonton

T8H ON2

Synergy Respiratory Care, Sherwood Park

V1W 1V3

Kelowna Respiratory and Allergy Cllinic, Kelowna

V7M 2H9

Mainra Rajesh R, Respirology, North Vancouver

V5Z 2S3

Vancouver General Hospital, Vancouver

V6Z 1Y6

St. Paul's Hospital University of British Colambia Division of Hematology, Vancouver

R3C ON2

Winnipeg Clinic, Winnipeg

E1C 5K4

Clinique de pneumologie de Moncton Respiratory Clinic, Moncton

E2M 5J7

Dr. Graham W. Bishop Clinic, Saint John

A1C 2H3

Professional Medical Corporation, St. John's

A1C 5B8

St. Clare'S Mercy Hospital, St. John's

L7N 3V2

Burlington Lung Clinic, Burlington

L8N 4A6

Firestone Institute for Respiratory Health, Hamilton

K7L 2V7

Hotel Dieu Hospital, Kingston

N6C 2R5

Lawson Health Research Institute a joint venture of LHSC Research Inc and Lawson Research Institute, London

L5M 2V8

Credit Valley Professional Building, Mississauga

L1H 1B9

Oshawa Clinic, Oshawa

K1Y 4G2

Carling Respiratory Services, Ottawa

N4K 3M6

Dr. Marc Newton Respirology, Owen Sound

M5G 2C4

Toronto General Hospital; Investigational Pharmacy Services ENB - 217 (Pharmacy Receiving), Toronto

N8X 5A6

Dr. Syed Anees Medicine Profession Corporation, Windsor

N8X-5A6

Dr Anil Dhar Professional Medicine Corporation, Windsor

H2L 4M1

Hopital Notre-Dame, Montreal

J6E 2B4

Clinique de pneumologie et du sommeil de Lanaudiere, Saint-Charles-Borromée

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02552849 - Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada | Biotech Hunter | Biotech Hunter